Repligen Co. (NASDAQ:RGEN) Shares Acquired by Congress Asset Management Co.

Congress Asset Management Co. grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 10.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,219 shares of the biotechnology company's stock after purchasing an additional 12,599 shares during the period. Congress Asset Management Co. owned about 0.23% of Repligen worth $16,442,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in RGEN. Signaturefd LLC increased its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in Repligen in the 4th quarter worth about $29,000. Raiffeisen Bank International AG purchased a new position in shares of Repligen during the fourth quarter worth approximately $29,000. Itau Unibanco Holding S.A. bought a new stake in shares of Repligen during the fourth quarter valued at approximately $40,000. Finally, Global Retirement Partners LLC boosted its holdings in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Up 2.6%

Shares of RGEN traded up $3.38 during midday trading on Monday, hitting $131.68. 626,274 shares of the company's stock traded hands, compared to its average volume of 748,876. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.40 billion, a price-to-earnings ratio of -258.20, a price-to-earnings-growth ratio of 4.54 and a beta of 1.10. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The firm's fifty day moving average is $127.28 and its 200-day moving average is $143.35.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period last year, the business posted $0.28 earnings per share. The firm's revenue was up 10.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on RGEN shares. JPMorgan Chase & Co. decreased their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Wall Street Zen upgraded Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Canaccord Genuity Group lowered their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. Finally, Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $173.25.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. The trade was a 31.53% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.